Delivery Order SPE2DB24D3014-SPE2DB25FKUMC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,282.52 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Orencia 125 mg/ml syringes. This firm fixed-price delivery order, which is expected to be completed by September 9, 2025, represents a small-value transaction within AmerisourceBergen's broader pharmaceutical supply portfolio for federal medical procurement. The award was made on a competitive, non-set-aside basis to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 7, 2025, for the supply of Orencia 125 mg/ml syringes valued at $8,772.35 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement extending through December 2026. The contract carries no set-aside designation and was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Orencia 125 mg/mL syringes, valued at $3,701.46. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $11,704.73 to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a single transaction under the company's larger pharmaceutical supply framework with the federal government. The product will be performed and delivered from AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Orencia 250 mg vials, a pharmaceutical product used in immunological treatment. This firm fixed-price delivery order, valued at $2,141.91, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The contract was...
- The Defense Logistics Agency awarded a $5,590.59 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Orencia 125 mg/ml syringes. This competitively awarded, firm fixed-price contract is not set-aside and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. Performance will be executed from the contractor's location in...
- The Defense Logistics Agency awarded a $10,711.89 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Orencia 125 mg/ml syringes. The contract carries a firm fixed price structure with no set-aside designation, reflecting competitive procurement procedures. The award is classified as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $3,570.63 on July 14, 2025, for the supply of Orencia 125 mg/ml syringes. This firm fixed price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $3,675.77 to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes. This contract, issued on June 18, 2025, with an ultimate completion date of June 20, 2025, represents a firm fixed-price procurement with no set-aside designation. The award was made competitively and reflects AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and healthcare systems. The place of performance is the company's...
- The Defense Logistics Agency awarded a delivery order valued at $31,595.86 to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes, with an ultimate completion date of September 17, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUMCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Orencia 125 mg/mL syringes valued at $7,796.46. This non-competitive delivery order is issued under a firm fixed price structure with a completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued against AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies a comprehensive range of pharmaceutical products and medical supplies to military and veteran healthcare systems. The company's DLA Troop Support Medical IDC serves as a global pharmaceutical support vehicle enabling the supply of specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. As a consistently competitive awardee with no set-aside designation, AmerisourceBergen demonstrates substantial capability in meeting federal procurement requirements for pharmaceutical products across varying transaction sizes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.8k | 8/27/25 |